Status:
COMPLETED
A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma
Lead Sponsor:
MEDA Pharma GmbH & Co. KG
Conditions:
Basal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the long-term sustained clearance rate of superficial basal cell carcinoma during a 5 year period following treatment with imiquimod
Eligibility Criteria
Inclusion
- Have one superficial BCC - primary tumour
- Minimum tumour area of 0.5cm2, maximum diameter of 2.0cm.
- If female and of child bearing potential, negative pregnancy test and willing to use medically acceptable method of contraception.
Exclusion
- Evidence of clinically significant, unstable medical conditions.
- Evidence of Gorlin syndrome, metastatic tumour or tumour with high probability of metastatic spread, have or have had within last 5 years other malignant cancers of the skin at target tumour site.
- Have received defined treatments in tumour site or surrounding area.
- Any dermatological disease in the target tumour site or surrounding area.
- Have had a systemic bacterial or viral infection within 2 weeks prior to study initiation.
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
160 Patients enrolled
Trial Details
Trial ID
NCT00189241
Start Date
February 1 2001
End Date
February 1 2007
Last Update
February 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Univertätsklinik für Dermatologie und Venerologie
Magedeburg, Germany